Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Featured Story from MarketBeat.com Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsWritten by Nathan Reiff. Article Published: 3/12/2026. 
Key Points - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: Have $500? Invest in Elon's AI Masterplan
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion over the next eight years. Companies often take a niche approach, developing medicines to address specific cancers with targeted mechanisms. Several promising treatments have shown significant potential—and with that comes the possibility of substantial sales. Two smaller biotech companies are enjoying notable share-price momentum thanks to their leading oncology medicines. Beyond offering strong therapeutic potential, these drugs could help the firms move beyond penny-stock or otherwise unstable status toward longer-term stability and profitability. That said, challenges remain, making these typical biotech investments high-risk ventures that could also deliver outsized rewards for investors willing to take a chance. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle Iovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% in a week when the S&P 500 fell about 1%. That added to IOVA's year-to-date (YTD) performance, which has seen shares more than double. Still, with a consensus price target of $8.88, Wall Street expects more from IOVA shares—that target implies about 71% upside from current levels. The major catalyst for Iovance's price movement is its lead drug, Amtagvi, a T-cell immunotherapy for certain types of melanoma. Amtagvi has been approved in the United States for melanoma since 2024 and has gathered momentum—both in sales and in expectations for additional approvals in the E.U., U.K., and elsewhere. When administered with Proleukin, the company's IL-2 immunotherapy, management believes Amtagvi could reach more than $1 billion in U.S. peak sales. Amtagvi's potential may extend beyond melanoma: the drug received FDA Fast Track Designation for non-small cell lung cancer and could be effective against multiple other tumor types. Some of Iovance's outperformance this year can also be traced to its Q4 2025 earnings report, issued in late February, in which the company posted narrower-than-expected losses per share and reported $5 million in revenue. For the full year, revenue rose roughly 30% year-over-year (YOY). Iovance is a small-biotech name with a market value near $2 billion and is often treated like a penny stock. Despite the strong rally, analysts remain cautious: about half of its roughly a dozen analyst ratings are Hold or Sell. Risks are high. In addition to the usual concerns around smaller biotech firms, Amtagvi's personalized, costly and complex manufacturing process could limit Iovance's ability to generate profit even as demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug Although ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, its YTD performance far outpaces Iovance's. IBRX shares are up nearly 300% in 2026 so far, and that may not be the end of the rally. Analysts' average price target of $13.60 represents roughly 70% upside from the stock's current price after this major uptick. ImmunityBio's primary growth driver is Anktiva, a treatment for specific types of bladder cancer. In February, shares jumped after the E.U. regulator granted the drug conditional marketing authorization, the latest in a series of approvals worldwide. Anktiva is already driving revenue: the drug generated $113 million in sales last year, a roughly 700% YOY increase. Like Amtagvi, Anktiva may have potential in additional cancer indications, and ImmunityBio is actively exploring alternative regulatory designations. Despite the dramatic gains over recent quarters, IBRX remains speculative and risky. The company posted a substantial full-year net loss of $351 million for 2025 as R&D expenses remain elevated. Still, Wall Street appears more bullish on ImmunityBio than on Iovance: six of seven analysts covering IBRX rate the shares a Buy or equivalent. | 
